Contracts › HT942525C0011
HT942525C0011: Dha Sttr Phase Ii Proposal H2-0803, Titled "Development of Antibody Treatment of Mdr Eskape Pathogen, P. Aeruginosa.", Medical R&D Contract.
Awarded to Fabrico Technology, Inc. by Defense Health Agency.
$1.3Mobligated
$1.3Mpotential value
11 July 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | HT942525C0011 |
|---|---|
| Awardee | Fabrico Technology, Inc. |
| Awarding agency | Defense Health Agency |
| Awarding office | ARMY MED RES ACQ ACTIVITY |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | TX |
| Offers received | 1 |
| Period of performance | 12 March 2025 to 11 July 2027 |
| Potential end | 11 July 2027 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record